RESUMO
Esophageal lichen planus is a rare condition, and although the majority of cases occur in conjunction with lichen planus at other sites, the endoscopic features are often misinterpreted resulting in a delay in diagnosis. We report a series of five patients presenting to our unit between 2005 and 2009. All five patients were female and presented with dysphagia. Endoscopy demonstrated proximal esophageal stricturing in four patients. Characteristic histological findings were found in four patients. Lichen planus was diagnosed at other sites, and preceded gastrointestinal symptoms, in all patients; five had oral involvement, two had genital involvement, and one had dermal involvement. All patients received proton pump inhibitor therapy without demonstrable benefit. Administration of oral fluticasone proprionate resulted in symptomatic improvement in three patients.
Assuntos
Androstadienos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Transtornos de Deglutição/patologia , Doenças do Esôfago/tratamento farmacológico , Líquen Plano/tratamento farmacológico , Doenças do Esôfago/diagnóstico , Esôfago/patologia , Feminino , Fluticasona , Humanos , Pessoa de Meia-Idade , Resultado do TratamentoAssuntos
Mucosa Gástrica/patologia , Pólipos/diagnóstico , Gastropatias/diagnóstico , Biópsia , Eletrocoagulação , Feminino , Mucosa Gástrica/cirurgia , Gastroscopia , Humanos , Hiperplasia , Pessoa de Meia-Idade , Pólipos/patologia , Pólipos/cirurgia , Reoperação , Gastropatias/patologia , Gastropatias/cirurgia , Resultado do TratamentoRESUMO
Twenty patients with carcinoma of the gallbladder (GB-4 patients) or extrahepatic bile ducts (EHBD-16 patients) received radiation therapy with curative intent between January, 1980 and December, 1982. All 20 received 4500-5000 rad in 180-200 rad fractions to the tumor and regional lymph nodes. A 1000 to 1500 rad external beam boost was delivered in 180-200 rad fractions in 10 patients who received external beam alone or concomitant 5-Fluorouracil (5-FU). Three of the four GB and 5 of the 16 EHBD patients received a transcatheter boost with 192-Iridium (192Ir) to a dose of 2000-2500 rad calculated at a 0.5-0.1 cm radius. An additional 2 patients with EHBD lesions received an intraoperative electron (IORT) boost of 1500-2000 rad in one fraction calculated to the 90% isodose. Survival and patterns of failure were analyzed by site and treatment method. All four patients with GB carcinoma are dead of disease at 5 1/2, 6, 9 and 10 months from the date of diagnosis respectively. Three of the four developed diffuse peritoneal carcinomatosis. Five of the 16 patients with EHBD carcinoma are alive with a median follow-up of 18 months (range 6-23 months). Four of the 5 patients received a transcatheter 192Ir or IORT boost and all are without evidence of disease. Four of 9 patients who had a subtotal resection with transection of tumor, dilatation of the bile ducts with probes or curettement of the bile ducts developed either diffuse peritoneal carcinomatosis (3 patients) or a recurrence in the surgical scar (2 patients). Local failure was documented in 3 of the nine patients treated with external beam alone +/- 5-FU, and has been documented in one of the seven patients who received an IORT or transcatheter 192Ir boost. Further experience is necessary to determine whether this aggressive treatment will result in long-term disease-free survival in these patients.
Assuntos
Neoplasias dos Ductos Biliares/radioterapia , Neoplasias da Vesícula Biliar/radioterapia , Adulto , Idoso , Neoplasias dos Ductos Biliares/tratamento farmacológico , Braquiterapia , Terapia Combinada , Elétrons , Feminino , Fluoruracila/uso terapêutico , Seguimentos , Neoplasias da Vesícula Biliar/tratamento farmacológico , Humanos , Período Intraoperatório , Irídio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Radioisótopos/uso terapêutico , Radioterapia de Alta EnergiaRESUMO
1. A non-invasive technique for the scintigraphic determination of 111indium-labelled platelet aggregation stimulated with submaximal doses of adenosine diphosphate (ADP, 56 micrograms kg-1 i.v.), collagen (100 micrograms kg-1 i.v.), platelet-activating factor (PAF, 0.1 microgram kg-1 i.v.) or thrombin (18 iu kg-1 i.v.) was used to investigate the platelet-inhibitory effects of endothelin 1 (ET-1) in anaesthetized rabbits in vivo. 2. ET-1 (1 nmol kg-1 i.v.) inhibited ADP-stimulated platelet aggregation in vivo; a maximum inhibition of 78% of the control value was reached at 3 min, with 45% inhibition at 15 min, and a return to control values at 30 min after injection of the peptide. 3. ET-1 (1 nmol kg-1 i.v.) inhibited in vivo platelet aggregation in response to collagen or PAF by 86% and 52%, respectively, but had no effect on thrombin-induced platelet aggregation. 4. Indomethacin (5 mg kg-1 i.v.) abolished the ET-1-induced inhibition of ADP-stimulated platelet aggregation and significantly potentiated and prolonged the pressor response brought about by ET-1. 5. In conclusion, the data demonstrate that ET-1 potently inhibits platelet aggregation in the anaesthetized rabbit in vivo by releasing a hypotensive and anti-aggregatory cyclo-oxygenase product, presumably prostacyclin, into the circulation.
Assuntos
Peptídeos/farmacologia , Inibidores da Agregação Plaquetária , Agregação Plaquetária/efeitos dos fármacos , Difosfato de Adenosina/farmacologia , Animais , Plaquetas/efeitos dos fármacos , Colágeno/farmacologia , Endotelinas , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Técnicas In Vitro , Radioisótopos de Índio , Masculino , Contração Miocárdica/efeitos dos fármacos , CoelhosRESUMO
1. Intravenous (i.v.) administration of adenosine diphosphate (ADP), platelet activating factor (PAF) and thrombin induced a dose-related accumulation of 111indium-labelled platelets within the thoracic region of anaesthetized rabbits. 2. I.v. administration of the inhibitor of NO biosynthesis, L-NG-nitro arginine methyl ester (L-NAME; 10 mg kg-1) significantly potentiated the peak platelet accumulation induced by ADP, PAF and thrombin. Additionally L-NAME prolonged the disaggregation of platelets in comparison to D-NAME (10 mg kg-1). Such changes were reversible by the administration of L-arginine (900 mg kg-1). 3. I.v. administration of PAF induced a small accumulation of 111indium-labelled neutrophils within the pulmonary circulation which could be greatly potentiated by pretreatment of the animals with L-NAME. In contrast, thrombin administration did not cause significant accumulation of 11indium-labelled erythrocytes in the pulmonary circulation of anaesthetized rabbits. 4. Intracarotid (i.c.) administration of thrombin induced a marked accumulation of radiolabelled platelets within the cranial vasculature which was not potentiated by the prior administration of L-NAME (at either 10 mg kg-1 or 100 mg kg-1). 5. These results suggest that endogenous NO may regulate platelet and polymorphonuclear leukocyte activation within the pulmonary but not the cerebral circulation of rabbits.
Assuntos
Neutrófilos/fisiologia , Óxido Nítrico/fisiologia , Ativação Plaquetária , Circulação Pulmonar , Difosfato de Adenosina/farmacologia , Animais , Arginina/análogos & derivados , Arginina/farmacologia , Circulação Cerebrovascular , Masculino , NG-Nitroarginina Metil Éster , Fator de Ativação de Plaquetas/farmacologia , CoelhosRESUMO
1. Intracarotid (i.c.) administration of thrombin induced a marked accumulation of 111indium-labelled platelets and 125I-labelled fibrinogen within the cranial vasculature of anaesthetized rabbits. 2. Thrombin (100 iu kg-1, i.c.) - induced platelet accumulation was completely abolished by pretreatment with desulphatohirudin (CGP 39393; 1 mg kg-1 i.c., 1 min prior to thrombin). Administration of CGP 39393 1 or 20 min after thrombin produced a significant reduction in platelet accumulation. 3. Intravenous (i.v.) administration of the platelet activating factor (PAF) receptor antagonist BN 52021 (10 mg kg-1) 5 min prior to thrombin (100 iu kg-1, i.c.) had no effect on platelet accumulation. 4. An inhibitor of NO biosynthesis, L-NG-nitro arginine methyl ester (L-NAME; 100 mg kg-1, i.c.), had no significant effect on the cranial platelet accumulation response to thrombin (10 iu kg-1, i.c.) when administered 5 min prior to thrombin. 5. Defibrotide (32 or 64 mg kg-1 bolus i.c. followed by 32 or 64 mg kg-1 h-1, i.c., infusion for 45 min) treatment begun 20 min after thrombin (100 iu kg-1, i.c.) did not significantly modify the cranial platelet accumulation response. 6. Cranial platelet accumulation induced by thrombin (100 iu kg-1, i.c.) was significantly reversed by the fibrinolytic drugs urokinase (20 iu kg-1, i.c., infusion for 45 min), anisoylated plasminogen streptokinase activator complex (APSAC) (200 micrograms kg-1, i.v. bolus) or recombinant tissue plasminogen activator (rt-PA; 100 micrograms kg-1, i.c. bolus followed by 20 micrograms kg-1 min-1, i.c., infusion for 45 min) administered 20 min after thrombin.8. These results suggest that neither endogenous PAF nor NO modulate thrombin-induced intracranial platelet accumulation in the rabbit. However, fibrin deposition appears to play an important role as shown by the ability of fibrinolytic agents to reverse platelet and fibrinogen accumulation induced by i.c. thrombin.
Assuntos
Diterpenos , Fibrinogênio/metabolismo , Embolia e Trombose Intracraniana/fisiopatologia , Óxido Nítrico/metabolismo , Fator de Ativação de Plaquetas/fisiologia , Trombina/farmacologia , Animais , Anistreplase/administração & dosagem , Anistreplase/farmacologia , Arginina/administração & dosagem , Arginina/análogos & derivados , Arginina/farmacologia , Plaquetas/metabolismo , Feminino , Fibrinolíticos/farmacologia , Ginkgolídeos , Hirudinas/administração & dosagem , Hirudinas/farmacologia , Injeções Intra-Arteriais , Injeções Intravenosas , Embolia e Trombose Intracraniana/induzido quimicamente , Lactonas/administração & dosagem , Lactonas/farmacologia , Masculino , NG-Nitroarginina Metil Éster , Óxido Nítrico/antagonistas & inibidores , Fator de Ativação de Plaquetas/antagonistas & inibidores , Agregação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Polidesoxirribonucleotídeos/administração & dosagem , Polidesoxirribonucleotídeos/farmacologia , Coelhos , Proteínas Recombinantes/farmacologia , Trombina/administração & dosagemRESUMO
1. The effects of lifarizine (RS-87476) on intracellular Ca2+ rises and the release of glutamate from rat cerebrocortical synaptosomes depolarized with 30 mM KCl were investigated by use of entrapped fura 2 and exogenous glutamate dehydrogenase. 2. Prior (1 min) addition of lifarizine decreased 30 mM KCl-induced total glutamate release, with 3 microM and 10 microM causing 39% and 72% averaged decreases from controls. The calcium-dependent component of glutamate release (approx. 40% of total) was similarly decreased by 47% and 74%, whereas the calcium-independent component was decreased by only 32% and 43% respectively. 3. In parallel experiments with fura-2-loaded synaptosomes, lifarizine reduced the depolarization-induced increases in intracellular [Ca2+], suggesting that this is the means by which the decreases in glutamate release are brought about. Lifarizine inhibited both the plateau and the spike phases of the Ca2+ increases suggesting that, in addition to its known sodium channel blocking properties, it may also inhibit more than one class of calcium channel in the synaptosomes. 4. Lifarizine at 1 microM and 3 microM also inhibited the rises in intracellular [Ca2+] in rat cultured cortical neurons depolarized with 60 mM KCl. 5. These effects of lifarizine on intracellular Ca2+ and glutamate exocytosis may contribute to its neuroprotective action.
Assuntos
Cálcio/metabolismo , Córtex Cerebral/efeitos dos fármacos , Exocitose/efeitos dos fármacos , Ácido Glutâmico/metabolismo , Imidazóis/farmacologia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Piperazinas/farmacologia , Sinaptossomos/efeitos dos fármacos , Animais , Células Cultivadas , Córtex Cerebral/metabolismo , Citosol/metabolismo , Masculino , Neurônios/metabolismo , Cloreto de Potássio/farmacologia , Ratos , Ratos Wistar , Canais de Sódio/efeitos dos fármacos , Sinaptossomos/metabolismoRESUMO
1. The ability of the neuroprotective agent, lifarizine (RS-87476), to mitigate veratridine-, cyanide- and glutamate-induced toxicity in rat embryonic cerebrocortical neurones in primary culture has been compared with that of tetrodotoxin (TTX), nitrendipine, (+)-MK-801 and (-)-MK-801. Lactate dehydrogenase (LDH) released into the culture medium was used as the indicator of cell viability. 2. Incubation of cultures for 16 h in a medium containing veratridine (10(-4) M), sodium glutamate (10(-3) M) or sodium cyanide (10(-3) M) resulted in consistent elevations of LDH activity in the culture medium. The ability of compounds to attenuate these elevations was expressed as the concentration required to inhibit the increases in LDH release by 50% (IC50). 3. Neurotoxicity induced by veratridine was inhibited by lifarizine (IC50 = 4 x 10(-7) M), TTX (IC50 = 3 x 10(-8) M) and nitrendipine (IC50 = 3 x 10(-5) M). In contrast, (+)-MK-801 (up to 3 x 10(-5) M) was ineffective against this insult. 4. Glutamate-induced neurotoxicity was inhibited by (+)-MK-801 (IC50 = 1.4 x 10(-8) M) and to a lesser extent by (-)-MK-801 (IC50 = 1 x 10(-7) M), but was unaffected by lifarizine, TTX or nitrendipine (up to 10(-6) M). 5. (+)-MK-801 was effective against sodium cyanide-induced neurotoxicity (IC50 = 1.9 x 10(-8) M), whereas lifarizine and TTX (up to 10(-6) M) and nitrendipine (up to 3 x 10(-6) M) were without protective activity against this insult. 6. The results demonstrate that lifarizine potently protects rat cortical neurones in vitro against a neurotoxic insult that requires activation of sodium channels for its expression, and that the compound is ineffective against insults mediated by N-methyl-D-aspartate receptor activation. The weak efficacy of nitrendipine against veratridine-induced cell death argues against the involvement of L-type calcium channels in this insult. These data are consistent with the notion that the neuroprotective activity oflifarizine observed in vivo may be mediated by inhibition of neuronal sodium currents.
Assuntos
Córtex Cerebral/efeitos dos fármacos , Imidazóis/farmacologia , Fármacos Neuroprotetores/farmacologia , Piperazinas/farmacologia , Animais , Células Cultivadas , Córtex Cerebral/metabolismo , Maleato de Dizocilpina/farmacologia , Relação Dose-Resposta a Droga , Feminino , Ácido Glutâmico/farmacologia , L-Lactato Desidrogenase/metabolismo , Ratos , Ratos Sprague-Dawley , Veratridina/farmacologiaRESUMO
The results of magnetic resonance imaging (MRI) examinations in the first 1,000 consecutive patients who were studied by this technique at our institution were reviewed to determine the disease states encountered, the sensitivity and accuracy of results, and the value of the examination as compared with computed tomography and other imaging procedures. The MRI device was a 0.15-tesla resistive magnet that used a variety of saturation recovery, spin echo, and inversion recovery pulse sequences to produce images. MRI was found equal to or superior to other imaging techniques in most cases. Exceptions included organs or body regions that are prone to excessive respiratory or vascular motion, lesions that necessitate exquisite spatial resolution for diagnosis, and lesions in which angulation of the viewing plane is necessary for optimal depiction. Fresh blood and calcification within a lesion were also difficult to detect with use of MRI.
Assuntos
Espectroscopia de Ressonância Magnética , Adolescente , Adulto , Idoso , Malformação de Arnold-Chiari/diagnóstico , Doenças Ósseas/diagnóstico , Doenças do Sistema Nervoso Central/diagnóstico , Criança , Pré-Escolar , Feminino , Neoplasias de Cabeça e Pescoço/diagnóstico , Humanos , Lactente , Recém-Nascido , Infecções/diagnóstico , Nefropatias/diagnóstico , Espectroscopia de Ressonância Magnética/instrumentação , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/diagnóstico , Doenças Musculares/diagnóstico , Mielografia , Neoplasias/diagnóstico , Convulsões/diagnóstico , Doenças Torácicas/diagnóstico , Tomografia Computadorizada por Raios X , Doenças Vasculares/diagnósticoRESUMO
Two patients with biliary cancer received radical radiation therapy. After treatment, both patients experienced episodes of biliary obstruction without definite evidence of progression of the tumor. These cases emphasize the importance of including radiation-induced biliary fibrosis in the differential diagnosis of hepatic duct stricture after radical radiation therapy.
Assuntos
Adenocarcinoma/radioterapia , Adenoma de Ducto Biliar/radioterapia , Neoplasias do Sistema Biliar/radioterapia , Colestase Extra-Hepática/diagnóstico , Recidiva Local de Neoplasia/diagnóstico , Lesões por Radiação/diagnóstico , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Lesões por Radiação/etiologiaRESUMO
Passage of stone fragments after extracorporeal shock wave lithotripsy (ESWL) of gallstones has resulted in biliary colic, duct obstruction, and pancreatitis in some patients. Rapid dissolution of these fragments with methyl tert-butyl ether (MTBE) may prevent such side effects and achieve complete clearance of gallstones within hours rather than several months to a year or longer. This study examines the safety of same-day ESWL fragmentation and MTBE dissolution of surgically implanted human gallstones in 15 dogs. The animals were randomly assigned to one of four treatment groups to assess MTBE absorption from the gallbladder and to observe hematology and chemistry profiles after 0, 400, and 1,200 shock waves from a lithotriptor followed by MTBE dissolution therapy. They were sacrificed either immediately after treatment (12 dogs) or 2 weeks later (3 dogs). The results demonstrated that although ESWL causes moderate trauma to the gallbladder, this did not result in increased MTBE absorption or histologic evidence of mucosal disruption. Blood profiles demonstrated an increase in only the level of aspartate aminotransferase. The three dogs that were sacrificed 2 weeks after the combined treatment had no residual evidence of gallbladder injury or remaining stone material. In all animals, severe injury occurred where shock waves passed through lung or air-filled colon. This study suggests that same-day sequential fragmentation of gallstones by ESWL followed by dissolution of stone fragments with use of MTBE may be associated with only mild to moderate and reversible gallbladder trauma and can rapidly achieve clearance of gallstones.
Assuntos
Colelitíase/terapia , Éteres/uso terapêutico , Litotripsia , Éteres Metílicos , Animais , Colecistografia , Colelitíase/diagnóstico por imagem , Colelitíase/patologia , Terapia Combinada , Cães , Litotripsia/métodosRESUMO
To define better the efficacy of bile acid therapy for dissolution of radiolucent gallstones, we performed a meta-analysis of published trials from January 1966 to September 1992. Studies were identified using a MEDLINE computer search followed by an extensive manual search. The inclusion criteria used were: randomized trial, radiolucent gallstones in a visualizing gallbladder on oral cholecystography, and complete stone dissolution confirmed by oral cholecystography or ultrasound. Study results were pooled into 6 groups: placebo: high- and low-dose chenodeoxycholic acid (CDCA) (> or = 10 mg.kg/day and < 10 mg.kg/day); high- and low-dose ursodeoxycholic acid (UDCA) (> or = 7 mg.kg/day and < 7 mg.kg/day) and combined CDCA plus UDCA. Homogeneity calculations were performed and the percentage of complete stone dissolution calculated for each group with 95% confidence intervals. Of 66 trials identified, 23 comprising 1949 patients met the inclusion criteria. A total of 1062 patients were treated with CDCA, 819 with UDCA and 78 combination therapy. In studies > 6 months' duration, high-dose UDCA completely dissolved stones in 37.3% of patients (95% C.I. 33-42%), low-dose UDCA in 20.6%) and high-dose CDCA 18.2% (95% C.I. 15-21%). Based on only two studies, combination therapy achieved dissolution in 62.8% (95% C.I. 51-74%) of patients. Stones less than 10 mm dissolved significantly more frequently than stones larger than 10 mm. This analysis shows that UDCA in doses greater than 7 mg.kg/day taken for greater than 6 months will dissolve radiolucent gallstones in 38% of patients. The combination of UDCA and CDCA may be more efficacious but this observation is based upon only 78 patients and requires confirmation in further randomized trials.
Assuntos
Ácido Quenodesoxicólico/uso terapêutico , Colelitíase/tratamento farmacológico , Ácido Ursodesoxicólico/uso terapêutico , Ácido Quenodesoxicólico/administração & dosagem , Quimioterapia Combinada , Humanos , MEDLINE , Ácido Ursodesoxicólico/administração & dosagemRESUMO
Carbachol (0.03-10 microM) or histamine (0.06-10 microM) challenge of indomethacin-pretreated rat aortic rings inhibited ADP-induced aggregation of platelets suspended in anticoagulated human whole blood. The maximum inhibition of platelet aggregation achieved with either drug was approximately 50%. No such inhibition was observed in rat aortic rings rubbed to remove endothelial cells or in intact vessels preincubated with nordihydroguaiaretic acid (NDGA, 10 microM), mepacrine (10 microM) or methylene blue (100 microM). Intravenously (i.v.) injected carbachol (0.5-5 micrograms/kg) also inhibited ADP-induced accumulation of 111indium-labelled platelets in the pulmonary circulation of urethane-anaesthetised rats. This effect of carbachol was inhibited by i.v. injected methylene blue (10 mg/kg) but unaffected by indomethacin (3 mg/kg) or hexamethonium (10 mg/kg) suggesting that PGI2 or adrenaline release did not account for the inhibition of platelet activation observed. Similarly, the platelet inhibitory effect of carbachol in vivo was not related to increased pulmonary vascular blood flow (assessed by accumulation of 111indium-labelled erythrocytes) or blood fibrinolytic activity (measured by euglobulin clot bioassay). The present results suggest that endothelium-derived relaxing factor or a like substance inhibits human platelet aggregation in vitro and rat platelet aggregation in vivo.
Assuntos
Fatores Biológicos/farmacologia , Agregação Plaquetária/efeitos dos fármacos , 6-Cetoprostaglandina F1 alfa/sangue , Animais , Fatores Biológicos/sangue , Pressão Sanguínea/efeitos dos fármacos , Carbacol/farmacologia , Fibrinólise/efeitos dos fármacos , Histamina/farmacologia , Humanos , Técnicas In Vitro , Radioisótopos de Índio , Masculino , Óxido Nítrico , Radioimunoensaio , Ratos , Fluxo Sanguíneo Regional/efeitos dos fármacosRESUMO
Percutaneous ultrasonic lithotripsy, endoscopically guided calculus fragmentation and removal through a percutaneous track, is the most widely used technique in the United States for removal of symptomatic upper urinary tract calculi. This article reviews the establishment of percutaneous renal access, track dilatation, and stone removal methods that constitute this technique.
Assuntos
Cálculos Renais/terapia , Terapia por Ultrassom/métodos , Humanos , Cálculos Renais/cirurgia , Terapia por Ultrassom/instrumentaçãoRESUMO
Forty-two patients with clinically suspected osteomyelitis were examined using magnetic resonance imaging (MRI). Twenty-seven patients (64%) had previous surgery or fracture, and 15 (36%) were referred for differentiation of acute osteomyelitis from bone tumors or other pathologic conditions. MRI was compared with computed tomography in 12 cases and with 111In-labeled leukocytes scans in 22. With MRI, 92% of proved infections were detected, and bone and soft-tissue changes were more evident than with routine radiographs, tomography, or computed tomography. In patients with negative cultures and no previous surgery or fracture, it was difficult for MRI to differentiate operative changes from infection. In these patients, 111In-labeled leukocyte images were more specific than MRI.
Assuntos
Espectroscopia de Ressonância Magnética , Miosite/diagnóstico , Osteomielite/diagnóstico , Adolescente , Adulto , Idoso , Neoplasias Ósseas/diagnóstico , Osso e Ossos/patologia , Diagnóstico Diferencial , Feminino , Humanos , Articulações/patologia , Leucócitos , Masculino , Pessoa de Meia-Idade , Músculos/patologia , Miosite/patologia , Osteomielite/patologiaRESUMO
Computed tomography (with and without contrast enhancement) provides excellent diagnostic accuracy for the evaluation of the chest. Oblique (55 degrees) and anteroposterior hilar tomography is accurate for the evaluation of hilar nodes and masses. Magnetic resonance techniques provide excellent differentiation of vascular and nonvascular structures and therefore should be useful in the hilum and mediastinum. Magnetic resonance imaging was used in 55 patients with known pathologic conditions in the mediastinum, hilum, and lungs to determine the accuracy and efficacy of this technique compared with computed and hilar tomography. The pathologic conditions included primary and metastatic neoplasms, benign masses, vascular abnormalities, and pulmonary nodules and infiltrates. Spatial resolution with magnetic resonance imaging is less than with computed tomography with our instrument (0.15 T resistive magnet). However, in the hilum and mediastinum, magnetic resonance imaging provided diagnostic information equal to that of computed tomography with contrast in 90% of patients. Vascular and nonvascular structures were more easily differentiated than with hilar tomography. Computed tomography was far superior in the evaluation of multiple pulmonary nodules. Lesions of the chest wall were better seen with magnetic resonance imaging because of the improved soft tissue contrast.
Assuntos
Neoplasias Pulmonares/diagnóstico , Espectroscopia de Ressonância Magnética , Doenças do Mediastino/diagnóstico , Neoplasias Torácicas/diagnóstico , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Humanos , Lactente , Neoplasias do Mediastino/diagnóstico , Pessoa de Meia-Idade , Tomografia , Tomografia Computadorizada por Raios X , Doenças Vasculares/diagnósticoRESUMO
OBJECTIVES: To assess the effectiveness of azathioprine in maintaining remission of quiescent Crohn's disease. SEARCH STRATEGY: Pertinent studies were selected using the MEDLINE data base (1966 - May 1998), the Cochrane Controlled Trials Register, the Inflammatory Bowel Disease Trials Register, as well as abstracts from major gastrointestinal research meetings and references from published articles and reviews. SELECTION CRITERIA: Five randomized, double-blind, placebo-controlled trials of azathioprine therapy were identified. Two of these trials consisted solely of patients with quiescent Crohn's disease. Three trials had multiple therapeutic arms for both induction of remission and maintenance of remission. DATA COLLECTION AND ANALYSIS: Data were extracted by three independent observers (GRM, GF, LRS) based on the intention to treat principle. Peto odds ratios for the overall maintenance of remission, steroid sparing, and withdrawals due to adverse effects were calculated, and from these, 95% confidence intervals were derived. Numbers needed to treat or harm (NNT, NNH respectively) for the maintenance of remission, steroid sparing, and withdrawals due to adverse effects were also determined. MAIN RESULTS: Azathioprine had a positive effect on maintaining remission. The Peto odds ratio for maintenance of remission was 2.16 (CI 1.35 - 3.47) with an NNT of 7. A higher dose improved response. A steroid sparing effect was noted, with a Peto odds ratio of 5.22 (CI 1.06 - 25.68) and NNT of 3 for quiescent disease. The Peto odds ratio for withdrawals due to adverse events was 4.36 (CI 1.63 - 11.67), the NNH (Number Needed to Harm) was 19. REVIEWER'S CONCLUSIONS: Azathioprine is effective in maintaining remission. There is evidence for a steroid sparing effect.
Assuntos
Azatioprina/uso terapêutico , Doença de Crohn/prevenção & controle , Imunossupressores/uso terapêutico , Azatioprina/efeitos adversos , Doença de Crohn/tratamento farmacológico , Humanos , Mercaptopurina/uso terapêutico , Pró-Fármacos/uso terapêuticoRESUMO
A case of C1 inhibitor deficiency presenting as localized edema of the small intestine is described. A 16-year-old, previously healthy woman presented with recurrent attacks of abdominal pain and vomiting following minor abdominal trauma. Investigations including computed tomography scan and barium studies confirmed localized edema of the jejunum. At laparoscopy, Crohn's disease was suspected; however, a subsequent enteroscopy was normal. Complement levels revealed a low C4 level, and C1 inhibitor deficiency was later confirmed. Attacks of abdominal pain began after starting oral contraceptives and have not returned since stopping the birth control pill. This rare cause of abdominal pain is examined, and C1 inhibitor deficiency and angioedema are reviewed.
Assuntos
Angioedema/complicações , Proteínas Inativadoras do Complemento 1/deficiência , Doença de Crohn/diagnóstico , Doenças do Jejuno/complicações , Dor Abdominal/etiologia , Adolescente , Angioedema/fisiopatologia , Feminino , HumanosRESUMO
Complications of bone marrow transplantation are numerous, multifactorial and may affect any organ in the body. The involvement of the gastrointestinal system represents one of dominant sites of complications. Clinical management of gastrointestinal complications can be challenging in these patients. This overview summarizes common bone marrow transplantation related conditions affecting esophagus, stomach, small and large intestine as well as liver. These are discussed primarily from the clinical point of view with emphasis on the differential diagnosis. The histomorphologic features of these conditions are discussed as well.